ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Expected to Post FY2024 Earnings of $3.45 Per Share

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) – Stock analysts at Capital One Financial issued their FY2024 EPS estimates for shares of ANI Pharmaceuticals in a research note issued to investors on Wednesday, September 11th. Capital One Financial analyst T. Chiang forecasts that the specialty pharmaceutical company will post earnings per share of $3.45 for the year. The consensus estimate for ANI Pharmaceuticals’ current full-year earnings is $3.50 per share. Capital One Financial also issued estimates for ANI Pharmaceuticals’ Q4 2024 earnings at $0.92 EPS and FY2025 earnings at $3.88 EPS.

A number of other equities analysts also recently issued reports on ANIP. Truist Financial reissued a “hold” rating and issued a $60.00 price objective (down previously from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Wednesday, August 7th. Finally, StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.75.

ANI Pharmaceuticals Stock Performance

ANIP opened at $56.20 on Monday. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. The company has a market cap of $1.18 billion, a price-to-earnings ratio of 35.04 and a beta of 0.71. The company’s 50 day moving average is $61.39 and its 200 day moving average is $63.93. ANI Pharmaceuticals has a 12-month low of $48.20 and a 12-month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.07. The firm had revenue of $138.00 million for the quarter, compared to the consensus estimate of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The business’s quarterly revenue was up 18.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.06 EPS.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 14,257 shares of the company’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total value of $900,472.12. Following the completion of the transaction, the chief operating officer now directly owns 635,363 shares in the company, valued at $40,129,527.08. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 14,257 shares of the company’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total value of $900,472.12. Following the completion of the transaction, the chief operating officer now directly owns 635,363 shares in the company, valued at $40,129,527.08. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Chad Gassert sold 20,000 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the completion of the transaction, the senior vice president now directly owns 193,226 shares in the company, valued at approximately $12,258,257.44. The disclosure for this sale can be found here. Insiders sold a total of 66,007 shares of company stock worth $4,089,790 over the last three months. 12.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds have recently modified their holdings of ANIP. Rubric Capital Management LP lifted its holdings in shares of ANI Pharmaceuticals by 32.8% in the fourth quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock worth $62,032,000 after buying an additional 277,989 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of ANI Pharmaceuticals by 1,005.8% in the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock worth $14,651,000 after buying an additional 209,272 shares in the last quarter. Global Alpha Capital Management Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 10.8% in the fourth quarter. Global Alpha Capital Management Ltd. now owns 582,428 shares of the specialty pharmaceutical company’s stock worth $32,115,000 after buying an additional 56,900 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of ANI Pharmaceuticals by 99.2% in the second quarter. American Century Companies Inc. now owns 99,831 shares of the specialty pharmaceutical company’s stock worth $6,357,000 after buying an additional 49,717 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of ANI Pharmaceuticals by 6.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company’s stock worth $32,628,000 after buying an additional 33,359 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.